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Background: Since the introduction of the sentinel lymph node (SLN) biopsy in breast
cancer patients there is a renewed interest in lymphatic drainage to the internal mammary (IM)
chain nodes. We evaluated the frequency of lymphatic drainage to the IM chain, the rate of
SLNs that contain metastases and the clinical implications of IM LN metastases.
Methods: Between June 1999 and April 2005 506 consecutive patients underwent SLN
biopsy as a staging procedure for clinically T1-2N0 breast cancer. In all patients preoperative
lymphoscintigraphy was combined with the intraoperative use of a gammaprobe. In patients
with IM SLNs visualized on lymphoscintigraphy, LNs were extirpated through an intercostal
parasternal incision.
Results: SLNs were visualized by preoperative lymphoscintigraphy in 99% of all patients
(502/506): axillary SLNs in 499 patients (99%), ipsilateral IM LNs in 109 patients (22%). In 85
patients with visualized IM SLNs the IM nodes could be removed (78%). In 20 of the latter 85
patients IM SLNs contained metastases (24%). IM metastases were associated with axillary
LN metastases (P < 0.001). In 17 patients IM metastases led to extension of the radiotherapy
ﬁeld, while additional (adjuvant) systemic therapy was given in six patients.
Conclusion: SLNs in the IM chain are common in breast cancer patients and can be
extirpated in the majority of these patients. The proportion of patients in whom radiothera-
peutic treatment was adjusted due to IM LN metastases was substantial. We advocate
retrieval of IM SLNs when visualized by preoperative lymphoscintigraphy.
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The internal mammary (IM) chain is well known as
a site of metastases in patients with breast cancer. The
presence of IM lymph node (LN) metastases is a poor
prognosticsignasreﬂectedbytheUICC-TNMstaging
system that classiﬁes IM LN metastases as stage N3.
1
In earlier times dissection of the IM LNs, as part of an
extended mastectomy with IM node dissection, was
advocated by some authors but randomized trials
failed to show any beneﬁcial effect of the procedure
that was accompanied by signiﬁcant morbidity.
2–4
Since then, interest in the IM LN chain has waned.
Since the introduction of the sentinel lymph node
(SLN) biopsy in breast cancer patients there has been
a renewed interest in the IM LNs. Drainage to this
basin is frequently seen on preoperative lympho-
scintigraphy, while the localization of the primary
tumor and the nanocolloid injection technique
appear to inﬂuence the frequency of visualized IM
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5–7 Various authors advocate removal of these
IM SLNs,
8,9 but the clinical implications of IM LN
biopsy are still unclear.
In this study we evaluated the frequency of lym-
phatic drainage to the IM chain, the rate of metas-
tases in the IM SLN and the clinical implications of
IM LN metastases.
PATIENTS AND METHODS
Between June 1999 and April 2005, 523 consecutive
patients underwent surgical treatment including SLN
biopsy as a staging procedure for clinically stage
T1-2N0 breast cancer. Data regarding all procedures
were collected prospectively in a database of the
nuclear medicine department.
A diagnosis of invasive breast cancer was estab-
lished preoperatively by ﬁne-needle aspiration or
image-guided large core needle biopsy. Sixteen
patients who underwent SLN biopsy as a secondary
operative procedure following previous excisional
biopsy of the primary tumor and one patient who
eventually turned out to have multicentric breast
cancer were excluded from the study.
The study cohort consisted of 506 patients. At the
time of the introduction of the sentinel node proce-
dure the ethical committee of the hospital approved
the routine use of the SLN biopsy as a staging pro-
cedure. All patients received written information
regarding the SLN procedure and the possibility of
SLNs in the IM chain. The unknown clinical impli-
cations of surgically removing IM LNs were dis-
cussed with the patients.
On the day of the operation, all patients received a
combination of peritumoral intraparenchymal and
subcutaneous injections of an average of 77.7 MBq
(53–150 MBq) of
99mTc nanocolloid in a total volume
of 0.6 ml of physiologic saline, given in two to three
equal doses. In case of a nonpalpable breast tumor the
tracer was injected around the tumor using a 7.5-MHz
ultrasoundprobe (Aloka). After injectionthe areawas
massaged until the appearance of the SLN. Continu-
ousvisualizationwasdoneandimagingstartedassoon
as lymphatic drainage was visualized on the persis-
tence scope and at 2–3 h after injection in both the
anterior and lateral direction. Images were obtained
during a 2-min imaging time on the Toshiba 901 HG
single-head gamma camera, using low-energy high-
resolution collimators. A skin marker was placed
on the projection of the SN using a handheld c-ray
detection probe (Europrobe, PI Medical diagnostic
equipment BV).
The operative procedure was carried out in the
afternoon of the same day of the
99mTc nanocolloid
injection. A c-ray detection probe and a peritumoral
injection of patent blue dye (Bleu patente ´ V, Labo-
ratoire Guerbet, Aulnay-sous-Bois, France) were in-
traoperatively used for SLN identiﬁcation. During
the operation axillary sentinel nodes were retrieved
ﬁrst and frozen section analysis was done to enable
axillary dissection during the same operative proce-
dure in case of LN metastases. When no axillary SLN
was visualized on preoperative lymphoscintigraphy,
the axilla was nonetheless explored in search for a
blue dye containing SLN. When no axillary SLN was
identiﬁed by either means, axillary LN dissection was
performed. Following retrieval of axillary SLNs,
surgical exploration for IM SLNs was done. When an
IM SLN was visualized on preoperative lympho-
scintigraphy, the c-ray detection probe was used to
guide a parasternal intercostal incision through the
best-suited intercostal space to harvest the visualized
node. A partial rib resection was not routinely done
for sentinel IM nodes that were localized behind the
ribs.
In addition to frozen section analysis of the axillary
SLNs, all collected SLNs were formalin-ﬁxed, par-
aﬃn embedded and cut at ﬁve levels of 250 lm.
Pathological evaluation followed hematoxylin-eosin
and immunohistochemical cytokeratin-8 staining.
The presence of axillary and IM LN metastases was
classiﬁed according to the 2002 version of the UICC-
TNM-classiﬁcation.
1
To assess the additional operative time of IM SLN
biopsy we compared the time between incision and
skin closure needed for lumpectomy and mastectomy
with and without IM SLN biopsy. We selected four
groups of ten patients: those who underwent lump-
ectomy with or without IM SLN biopsy and those
who had had mastectomy with or without IM SLN
biopsy. In all patients the operative procedure had
started with axillary SLN biopsy. We only evaluated
patients who did not have axillary dissection to avoid
the potential bias of extra time awaiting the result of
frozen section analysis. For each category we selected
the last ten patients to avoid the learning curve eﬀect.
To evaluate the impact of IM LN metastases on
subsequent systemic treatment we assessed the pro-
posed adjuvant treatment strategy in the absence and
presence of metastases in these nodes, applying the
Dutch national guidelines for treatment of breast
cancer (version 2005, http//www.oncoline.nl, sum-
marized in Table 1). Locoregional radiotherapy,
comprising the affected breast and/or thoracic
wall, and the ipsilateral axillary, periclavicular and
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or more metastatic axillary LNs. In patients with IM
LN metastases with 0–3 tumor-positive axillary LNs
a parasternal irradiation was given: in combination
with irradiation of the breast in patients who had
breast-conserving therapy or as parasternal radio-
therapy following mastectomy.
Chi-square analysis was performed to evaluate
diﬀerences in IM SLN visualization rates between
groups of patients with various clinicopathological
variables and to explore the relation between IM and
axillary LN metastases. The ANOVA test was used
to explore the relation between age and the visuali-
zation of IM SLNs, as well as for the analysis of
operative time diﬀerences.
RESULTS
The median age of the 506 patients was 60 years
(range 24–92 years) and there were three male pa-
tients (0.8%). The distribution of primary tumor
characteristics is summarized in Table 2.
Visualization and Retrieval of Sentinel Lymph Nodes
in the IM Chain (Fig. 1)
SLNs were visualized on preoperative lympho-
scintigraphy in 502 of the 506 patients (99%). Axillary
SLNs were visualized in 499 of 502 patients (99%),
while one or more IM SLNs were found in 109 pa-
tients (22%). Three of the 109 patients with visualized
IM SLNs had IM sentinel nodes only (3%); in one of
these latter patients, an axillary SN was removed
following patent blue dye injection and axillary
exploration. Location of the tumor in the craniome-
dial and caudomedial aspect of the breast was
associated with drainage to the IM nodes
(P < 0.001), and patients with visualized internal
mammary nodes were younger (Table 2).
IM SLNs could be retrieved through a parasternal
intercostal incision in 85 of the 109 patients (78%).
Parasternal exploration for IM SLNs added 16 min
to the mean operative time in patients who underwent
breast conservative therapy (P = 0.02). For patients
who underwent mastectomy the operative time was
not signiﬁcantly prolonged (Table 3). Complications
(pleural breeching, internal mammary vessel damage)
of the intercostal surgical exploration were rare; in
particular there were no pneumothoraxes or bleeding
complications necessitating drainage or reoperation
(Table 4).
IM LN Metastases
Metastases in the IM SLN were observed in 20 of
the 85 patients who underwent successful IM SLN
exploration (24%), and 42% of the patients with
axillary SLNs (210/499). There was a correlation
between IM metastases and axillary metastases
TABLE 1. Indications for adjuvant chemo- and hormonal
systemic therapy according to the Dutch national guidelines
2005
Axillary lymph node metastases
Primary tumor characteristics
Tumor >3 cm
Tumor >2 cm and BR grade II
Tumor >1 cm and BR grade III
Other conditions
Age <35 years: always systemic therapy
60-69 years: chemotherapy when
ER- or ‡4 axillary lymph node metastases
‡70 years: no chemotherapy
ER status Hormonal therapy for the aforementioned
indications at all ages if the tumor is
ER receptor positive.
BR, Bloom-Richardson; ER, estrogen receptor.
IM SLN visualized 
109
no IM SLN visualized 
397
 IM SLN not removed
24
IM SLN removed 
85
17 exclusions
previous excisional biopsy 16
multicentric cancer  1 
eligible patients 
506
SLN biopsy for cT1-2N0 
breast cancer
523
IM lymph node metastases no IM lymph node metastases
20 65
FIG. 1. Summary of search for internal mammary sentinel lymph
nodes (IM SLNs).
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metastases, the axillary SLN contained metastases
too (80%). Conversely, IM metastases were found in
1% of patients without axillary metastases (4/297), in
7% of patients with 1–3 axillary metastases (13/174)
and in 8 % of patients with ‡4 axillary metastases
(3/36).
Clinical Implications of Metastases in the IM SLN
(Table 5)
Adjuvant systemic therapy was already indicated in
14 of the 20 patients with IM metastases due to
concomitant axillary LN metastases or unfavorable
primary tumor characteristics: ten patients would be
candidates for postoperative chemotherapy and 14
TABLE 2. Comparison of characteristics of patients who had visualized internal mammary sentinel lymph nodes (IM SLNs)
versus those who had not visualized IM SLNs on preoperative lymphoscintigraphy
All patients IM SLN visualized IM SLN not visualized
P n = 506 n = 109 n = 397
Median age (years) 60 (range 24–92) 57 (range 30–91) 61 (range 24–92) 0.016*
Gender 0.36
Male 3 (0.6) 0 (0) 3 (0.8)
Female 503 (99.4) 109 (100) 394 (99.2)
T-stage 0.47
T1 316 (62.5) 73 (67.0) 243 (61.2)
T2 184 (36.4) 36 (33.0) 148 (37.3)
T3 4 (0.8) 0 (0) 4 (1.0)
Tx 2 (0.4) 0 (0) 2 (0.5)
Tumor localization <0.001
Cranial 47 (9.3) 11 (10.1) 36 (9.1)
Craniolateral 230 (45.5) 30 (27.5) 200 (50.4)
Lateral 25 (4.9) 2 (1.8) 23 (5.8)
Caudolateral 40 (7.9) 10 (9.2) 30 (7.6)
Caudal 18 (3.6) 1 (3.6) 17 (4.3)
Caudomedial 30 (5.9) 13 (11.9) 17 (4.3)
Medial 11 (2.2) 4 (3.7) 7 (1.8)
Craniomedial 80 (15.8) 34 (31.2) 46 (11.6)
Central 25 (4.9) 4 (3.7) 21 (5.3)
Malignancy grade 0.63
BRI 206 (40.7) 48 (44.0) 158 (39.8)
BRII 196 (38.7) 38 (34.9) 158 (39.8)
BRIII 104 (20.6) 23 (21.1) 81 (20.4)
Estrogen receptor status 0.24
Positive 427 (84.4) 88 (80.7) 339 (85.4)
Negative 79 (15.6) 21 (19.3) 58 (14.6)
Axillary lymph node involvement 0.58
No axillary metastases 296 (58.5) 68 (62.4) 228 (57.4)
1–3 lymph node metastases 174 (34.4) 35 (32.1) 139 (35.0)
*4 lymph node metastases 36 (7.1) 6 (5.5) 30 (7.6)
Values in parentheses are percentages.
BR, Bloom-Richardson grade.
* Age diﬀerence between the groups was compared by ANOVA.
TABLE 3. Operative time of surgical exploration for
internal mammary sentinel lymph nodes (IM SLNs)
(n = 40)
Mean operative time in minutes (range) P
Axillary SLN biopsy/lumpectomy/
IM SLN biopsy
60 (27–76) 0.02
Axillary SLN biopsy/lumpectomy/
no IM SLN biopsy
44 (32–83)
Axillary SLN biopsy/mastectomy/
IM SLN biopsy
72 (42–104) 0.8
Axillary SLN biopsy/mastecomy/
no IM SLN biopsy
69 (30–100)
TABLE 4. Complications of surgical exploration for
internal mammary sentinel lymph nodes (IM SLNs)
(n = 109)
n
Intraoperative complications
Pleural breeching 4 (4)
Internal mammary vessel damage 6 (6)
Postoperative complications
Pneumothorax )
Bleeding necessitating reoperation )
Values in parentheses are percentages.
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positive IM SLNs six additional patients would re-
ceive systemic treatment. This proportion reﬂects 7%
of the patients in whom IM SLNs were removed. In
four patients chemotherapy was indicated and in ﬁve
patients hormonal therapy.
In 3 of the 20 patients axillary tumor load (‡4
tumor-positive lymph nodes) was a reason for lo-
coregional radiotherapy including the IM lymphatic
chain, leaving 17 patients in whom the radiotherapy
ﬁeld was adjusted because of metastases in the IM
SLN. These 17 patients in whom the radiothera-
peutic strategy was changed made up 20% of
the patients in whom IM sentinel nodes were
visualized.
Conversely, there were three patients with ‡4
axillary metastases and IM SLNs without metastases,
and in these patients parasternal irradiation was
omitted. In addition, parasternal irradiation could
also be omitted in 30 patients with ‡4 axillary
metastases who had no IM lymphatic drainage on
preoperative lymphoscintigraphy.
DISCUSSION
In the present study, SLNs in the IM chain were
visualized in approximately one-ﬁfth of the patients
who underwent surgery for primary breast cancer.
Retrieving these nodes by parasternal intercostal
exploration was feasible in the majority of patients.
One-ﬁfth of the retrieved IM LNs contained metas-
tases and radiation treatment was adjusted in most of
these patients.
In this prospective cohort of patients who under-
went SLN biopsy for clinically T1-2N0 breast cancer,
IM SLNs were seen on the preoperative lympho-
scintigraphy in 22% of the patients.
5,6,8,10,11 The
visualization rate in our study was rather high and
the likely result of the tracer injection technique
TABLE 5. Clinical postsurgical implications of internal mammary lymph nodes IM LN metastases (n = 20)
No.
Tumor characteristics
Axillary
metastases
Postsurgical treatment
Treatment changed due
to IM metastases
IM SLN not
considered
IM SLN
considered
Size (cm) Grade (BR) ER (n) C TH TR T C TH TR T
Axilla N4+/age<70
1) 63, BCT 1.5 I + 7 + + LR + + LR No
2) 45, BCT 1.6 III + 4 + + LR + + LR No
3) 47, mastectomy 1.8 I + 4 + + LR + + LR No
Axilla N1-3+/age<70
4) 39, mastectomy 2.5 II + 3 + + BCT + + BCT+PS RT
5) 46, BCT 3.5 III ) 3+ ) BCT + ) BCT+PS RT
6) 58, BCT 1.8 II + 2 + + BCT + + BCT+PS RT
7) 45, BCT 2.4 I + 2 + + BCT + + BCT+PS RT
Axilla N1-N1a or unfavorable primary tumor characteristics/age<70
8) 43, BCT 1.8 I + 1mi ))BCT + + BCT+PS CT/HT/RT
9) 54, BCT 2.2 II + 1mi + + BCT + + BCT+PS RT
10) 66, BCT 2.5 II + 1mi ) + BCT ) + BCT+PS RT
11) 50, BCT 2.5 III + 1mi + + BCT + + BCT+PS RT
12) 42, mastectomy 3.0 I + 1 + + No + + PS RT
Axilla N0/favorable tumor characteristics/age<70
12) 54, BCT 2.1 I + 0 ))BCT + + BCT+PS CT/HT/RT
14) 60, BCT 2.5 I + 0 ))BCT + + BCT+PS CT/HT/RT
15) 67, mastectomy 0.8 I + 0 ))No ) + PS HT/RT
16) 61, BCT 1.1 I ) 0 ))BCT + ) BCT+PS CT/RT
Age>70
17) 82, mastectomy 2.8 II + 2 ) +N o) + PS? RT?
18) 71, BCT 2.1 II + 1 ) + BCT ) + BCT+PS RT
19) 72, BCT 2.1 II + 1mi ) + BCT ) + BCT+PS RT
20) 85, mastectomy 0.9 I + 1mi ))No ) + PS? HT/RT?
BCT, breast-conserving therapy; BR, Bloom-Richardson grade; ER, estrogen receptor status; Nax+, number of positive axillary lymph
nodes; IM SLN, internal mammary sentinel lymph node; ST, systemic therapy; CT, chemotherapy; HT, hormonal therapy; RT, radiotherapy;
PS, parasternal radiotherapy; 1mi, micrometastases.
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tous peritumoral and a subcutaneous injection tech-
nique of the
99mTc nanocolloid, and this technique is
associated with a higher visualization rate of IM
SLNs than the subcutaneous or periareolar injection
of the radiotracer.
5–7,12,13 Apart from the effect of the
injection technique we observed a higher frequency of
lymphatic drainage to the IM LNs in patients with
cranio- and caudomedially located tumors, as re-
ported by others,
8,14,15 as well as an effect of age: IM
SLNs were more common in young patients.
Retrieving SLNs from the IM chain does not ap-
pear to be very troublesome. Approximately 15 min
extraoperative time is needed during breast conser-
vative surgery, while extra time is negligible in
patients who undergo mastectomy. Although the
success rate was lower than for SLNs in the axilla,
78% of the visualized IM nodes could be harvested by
the described parasternal intercostal exploration.
Others reported similar surgical identiﬁcation rates
(69–88%, see Table 6).
5,6,8,10,11 It can be difﬁcult to
retrieve the usually very small IM SLNs when they
are localized directly behind one of the ribs. Blind
retrocostal dissection is not without risks, and we
consider a rib resection not justiﬁed as long as
the place of parasternal lymph node exploration is
not well deﬁned. Although the pleural cavity was
breeched occasionally during the procedure and a
number of patients had postoperative hematomas,
postoperative drainage of a pneumothorax or a re-
operation for a bleeding complication of the paras-
ternal wound was never necessary. Other studies also
reported low morbidity rates.
8,9,11,16,17
InthepresentstudyIMLNmetastaseswerefoundin
24% of the patients who underwent surgical extirpa-
tion of these SLNs, while others usually reported
lower rates of metastases containing IM SLNs
(9–26%).
8–11,18 In patients with IM metastases axillary
metastases were common: 80% had concomitant
axillary metastases.
19 Conversely, axillary metastases
wereaccompaniedbyIMmetastasesin8%ofthecases.
Isolated IM metastases were rare affecting 5% of the
patients with harvested IM SLNs and approximately
1% of patients without axillary LN metastases.
8,10,19
Successful exploration of SLNs from the IM chain
had a substantial impact on subsequent radiothera-
peutic treatment. In 20% of these patients adjustment
of radiotherapy was considered necessary. Although
randomized data about the use of radiotherapy in
patients with IM metastases are lacking, adding a
parasternal irradiation in these patients appears
conceivable. After all radiotherapy does aﬀect loco-
regional control in other high-risk patient groups
such as patients with ‡4 axillary metastases and node-
negative patients with young age, poor tumor diﬀer-
entation and large tumor size.
20 We consider patients
with IM metastases at risk for locoregional recur-
rence and therefore feel that parasternal irradiation is
indicated in patients with IM metastases. Conversely,
absence of IM lymphatic drainage or metastases in
retrieved IM SLNs justiﬁed omission of parasternal
radiotherapy in 7% of all the patients.
Systemic treatment strategy was rarely inﬂuenced
by IM metastases. Due to axillary metastases and
unfavorable primary tumor characteristics, half of
the patients already would have received chemo-
therapy and even more would have had hormonal
therapy. In the remaining group of patients, old age
and negative estrogen receptor status further limited
the proportion of patients that would receive
adjuvant systemic therapy based on IM LN metas-
tases. However, since prognosis of patients with both
axillary and IM metastases is poor when compared
with axillary or IM metastases alone,
3 patients with
IM and axillary metastases might need different
chemotherapy schedules. That would increase the
proportion of patients in whom adjuvant systemic
treatment would be adjusted.
Is IM SLN biopsy worthwhile? One may argue that
more extensive radiotherapy was indicated in less
than 5% of all patients and additional systemic
treatment in only 1%, and thus consider IM SLN
biopsy hardly ‘‘worth the eﬀort.’’
10 We feel that the
group of patients with visualized SLNs should be
TABLE 6. Visualization and surgical extirpation rate of internal mammary sentinel lymph nodes (IM SLNs) in breast cancer
patients
Author Year n Method of tracer injection Visualized IM SLNs (%) Surgically removed IM SLNs (%)*
Madsen et al. 2006 506 PT and SC 22 78
Leidenius et al.
10 2005 984 IT 14 88
Paredes et al.
6 2005 383 SC, later IT/PT 0–17 73
Farrus et al.
5 2004 225 SC, later IT/PT 11–17 69
Estourgie et al.
8 2003 681 IT 22 87
van der Ent et al.
11 2002 256 PT 25 63
* Proportion of the visualized IM SLNs. SC, subcutaneous; PT, peritumoral; IT, intratumoral.
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tients in whom less radiotherapy was given should
also be taken into account. As a consequence, we do
consider the clinical implications of IM SLN biopsy
substantial.
In conclusion, lymphatic drainage of breast cancer
to IM LNs is a common feature and retrieving these
nodes is relatively easy. The clinical impact of
metastases in IM lymph nodes is substantial and
justiﬁes surgical exploration for these nodes. We
advocate routine parasternal intercostal exploration
for IM SLNs whenever preoperative lymphoscintig-
raphy visualizes IM SLNs. For that purpose we also
advocate the (additional) intraparenchymatous tracer
injection to optimize the visualization of IM SLNs.
REFERENCES
1. UICC TNM classiﬁcation of malignant tumours. New York:
Wiley Liss, 2002.
2. Lacour J, Le MG, Hill C, et al. Is it useful to remove internal
mammary nodes in operable breast cancer? Eur J Surg Oncol
1987; 13:309–314.
3. Veronesi U, Cascinelli N, Greco M, et al. Prognosis of breast
cancer patients after mastectomy and dissection of internal
mammary nodes. Ann Surg 1985; 202:702–707.
4. Veronesi U, Marubini E, Mariani L, et al. The dissection of
internal mammary nodes does not improve the survival of
breast cancer patients. 30-year results of a randomised trial.
Eur J Cancer 1999; 35:1320–1325.
5. Farrus B, Vidal-Sicart S, Velasco M, et al. Incidence of internal
mammary node metastases after a sentinel lymph node tech-
nique in breast cancer and its implication in the radiotherapy
plan. Int J Radiat Oncol Biol Phys 2004; 60:715–721.
6. Paredes P, Vidal-Sicart S, Zanon G, et al. Clinical relevance of
sentinel lymph nodes in the internal mammary chain in breast
cancer patients. Eur J Nucl Med Mol Imag 2005; 32:1283–1287.
7. Rubello D, Zavagno G, Bozza F, et al. Analysis of technical
and clinical variables affecting sentinel node localization in
patients with breast cancer after a single intradermal injection
of 99mTc nanocolloidal albumin. Nucl Med Commun 2004;
25:1119–1124.
8. Estourgie SH, Tanis PJ, Nieweg OE, et al. Should the hunt for
internal mammary chain sentinel nodes begin? An evaluation
of 150 breast cancer patients. Ann Surg Oncol 2003; 10:935–
941.
9. Galimberti V, Veronesi P, Arnone P, et al. Stage migration
after biopsy of internal mammary chain lymph nodes in breast
cancer patients. Ann Surg Oncol 2002; 9:924–928.
10. Leidenius MH, Krogerus LA, Toivonen TS, et al. The clinical
value of parasternal sentinel node biopsy in breast cancer. Ann
Surg Oncol 2006; 13:321–326.
11. van der Ent FW, Kengen RA, van der Pol HA, et al. Halsted
revisited: internal mammary sentinel lymph node biopsy in
breast cancer. Ann Surg 2001; 234:79–84.
12. Knox SM, Ley CA. Comparison of intraparenchymal and
intradermal injection for identiﬁcation of the sentinel node in
patients with breast cancer. Proc (Bayl Univ Med Cent) 2002;
15:366–368.
13. Krynyckyi BR, Kim CK, Goyenechea MR, et al. Clinical
breast lymphoscintigraphy: optimal techniques for performing
studies, image atlas, and analysis of images. Radiographics
2004; 24:121–145.
14. Bevilacqua JL, Gucciardo G, Cody HS, et al. A selection
algorithm for internal mammary sentinel lymph node biopsy in
breast cancer. Eur J Surg Oncol 2002; 28:603–614.
15. Byrd DR, Dunnwald LK, Mankoff DA, et al. Internal mam-
mary lymph node drainage patterns in patients with breast
cancer documented by breast lymphoscintigraphy. Ann Surg
Oncol 2001; 8:234–240.
16. Dupont EL, Salud CJ, Peltz ES, et al. Clinical relevance of
internal mammary node mapping as a guide to radiation
therapy. Am J Surg 2001; 182:321–324.
17. Johnson N, Soot L, Nelson J, et al. Sentinel node biopsy and
internal mammary lymphatic mapping in breast cancer. Am J
Surg 2000; 179:386–388.
18. Hong J, Chog E, Soni N, et al. Extra-axillary sentinel node
biopsy in the management of early breast cancer. Eur J Surg
Oncol 2005; 31:942–948.
19. Cserni G, Szekeres JP. Internal mammary lymph nodes and
sentinel node biopsy in breast cancer. Surg Oncol 2001; 10:25–
33.
20. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy
and of differences in the extent of surgery for early breast
cancer on local recurrence and 15-year survival: an overview of
the randomised trials. Lancet 2005; 366:2087–2106.
E. V. E. MADSEN ET AL. 1492
Ann. Surg. Oncol. Vol. 14, No. 4, 2007